KCKarolina Cyll

Karolina Cyll

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karolina Cyll has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Hanne A. Askautrud

    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway

    2 shared publications
  • Håvard E. Danielsen

    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway

    2 shared publications
  • Ljiljana Vlatkovic

    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway

    2 shared publications
  • Andreas Kleppe

    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway; Centre for Research-based Innovation Visual Intelligence, UiT The Arctic University of Norway, Tromsø, Norway

    1 shared publication
  • Anita Langerød

    1 shared publication
  • Anne-Lise Børresen-Dale

    1 shared publication

Latest Publications

  • Open Access

    DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance

    by Karolina Cyll, Erik Skaaheim Haug, Manohar Pradhan, Ljiljana Vlatkovic, Birgitte Carlsen, Sven Löffeler, Wanja Kildal, Karin Skogstad, Frida Hauge Torkelsen, Rolf Anders Syvertsen, et al.

    Background: Current risk stratification tools for prostate cancer patients under active surveillance (AS) may inadequately identify those needing treatment. We investigated DNA ploidy and PTEN as potential biomarkers to predict aggressive disease in AS patients. Methods: We assessed DNA ploidy by image cytometry and PTEN protein expression by immunohistochemistry in 3197 tumour-containing tissue blocks from 558 patients followed in AS at a Norwegian local hospital. The primary endpoint was treatment, with treatment failure (biochemical recurrence or initiation of salvage therapy) as the secondary endpoint. Results: The combined DNA ploidy and PTEN (DPP) status at diagnosis was associated with treatment-free survival in univariable- and multivariable analysis, with a HR for DPP-aberrant vs. DPP-normal tumours of 2.12 (p < 0.0001) and 1.94 (p < 0.0001), respectively. Integration of DNA ploidy and PTEN status with the Cancer of the Prostate Risk Assessment (CAPRA) score improved risk stratification (c-index difference = 0.025; p = 0.0033). Among the treated patients, those with DPP-aberrant tumours exhibited a significantly higher likelihood of treatment failure (HR 2.01; p = 0.027). Conclusions: DNA ploidy and PTEN could serve as additional biomarkers to identify AS patients at increased risk of developing aggressive disease, enabling earlier intervention for nearly 50% of the patients that will eventually receive treatment with current protocol.


  • Open Access

    Deep learning for automated scoring of immunohistochemically stained tumour tissue sections – Validation across tumour types based on patient outcomes

    by Wanja Kildal, Karolina Cyll, Joakim Kalsnes, Rakibul Islam, Frida M. Julbø, Manohar Pradhan, Elin Ersvær, Neil Shepherd, Ljiljana Vlatkovic, Xavier Tekpli, et al.